Condition: Inferior Alveolar Nerve Injuries · Sponsor: Cleveland Dental Institute
This research aims to evaluate of the risk of nerve damage following the administration of articaine 4% and lidocaine 2% for Inferior Alveolar nerve Block (IANB). A Randomized Controlled Clinical Trial will be conducted where the patient will be randomly assigned to one the two groups; articaine 4% and Lidocaine 2%. The type of LA will be concealed to the operator, investigators and assessors. The patients will be monitored for any aigns of nerve parathesia for 3 months after the procedure.
This description comes directly from the study's public registry record.
Pablo R Velazquez, Resident · 7546108595 · p.velazquez@cdiohio.org
Nelson A Rendon, Resident · 9548605748 · n.rendon@cdiohio.org
Always discuss trial participation with your own doctor first.
| Cleveland Dental Institute | Akron, Ohio, United States | Recruiting |
| Cleveland Dental Institute | Ashtabula, Ohio, United States | Active Not Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06564987